Doximity Announces Fiscal 2026 Third Quarter Financial Results

02/05/2026

Total revenues of $185.1 million, up 10% year-over-year

Net income of $61.6 million, margin of 33%

Adjusted EBITDA of $111.4 million, margin of 60%

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 third quarter ended December 31, 2025.

“We’re proud to deliver another quarter of strong profits and record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. “Our newsfeed had more than 1 million quarterly active prescribers, our workflow products had 720,000 (a record QoQ jump), and our nascent AI products had over 300,000. In short, the addition of AI features across our platform has made us more useful than ever.”

Fiscal 2026 Third Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended December 31, 2024.

  • Revenue: Revenue of $185.1 million, versus $168.6 million, an increase of 10% year-over-year.
  • Net income and non-GAAP net income: Net income of $61.6 million, versus $75.2 million, representing a margin of 33.3%, versus 44.6%. Non-GAAP net income of $91.1 million, versus $91.4 million, representing a margin of 49.3%, versus 54.2%.
  • Adjusted EBITDA: Adjusted EBITDA of $111.4 million, versus $102.0 million, an increase of 9% year-over-year, representing adjusted EBITDA margins of 60.2%, versus 60.5%.
  • Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.31, versus $0.37, while non-GAAP diluted net income per share was $0.46, versus $0.45.
  • Operating cash flow and free cash flow: Operating cash flow of $60.9 million, versus $65.2 million, a decrease of 7% year-over-year, and free cash flow of $58.5 million, versus $63.4 million, a decrease of 8% year-over-year.

Financial Outlook

Doximity is providing guidance for its fiscal fourth quarter ending March 31, 2026 as follows:

  • Revenue between $143 million and $144 million.
  • Adjusted EBITDA between $63.5 million and $64.5 million.

Doximity is updating guidance for its fiscal year ending March 31, 2026 as follows:

  • Revenue between $642.5 million and $643.5 million.
  • Adjusted EBITDA between $355.5 million and $356.5 million.

Stock Repurchase Program

Doximity’s board of directors authorized another program to repurchase up to $500 million of the Company’s Class A common stock. The repurchase program has no expiration date and is subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans.

Conference Call Information

Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. With new AI-powered clinical reference and search capabilities, Doximity also helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DOXIMITY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

December 31, 2025

March 31, 2025

Assets

Current assets:

Cash and cash equivalents

$

64,838

$

209,614

Marketable securities

670,288

706,050

Accounts receivable, net

156,589

128,354

Prepaid expenses and other current assets

101,738

44,602

Total current assets

993,453

1,088,620

Property and equipment, net

17,055

13,656

Deferred income tax assets

14,842

60,014

Operating lease right-of-use assets

7,523

8,886

Intangible assets, net

37,266

23,072

Goodwill

84,973

67,940

Other assets

1,914

2,121

Total assets

$

1,157,026

$

1,264,309

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

4,785

$

1,356

Accrued expenses and other current liabilities

76,677

38,405

Deferred revenue, current

66,307

114,285

Operating lease liabilities, current

2,079

2,211

Total current liabilities

149,848

156,257

Deferred revenue, non-current

174

280

Operating lease liabilities, non-current

8,613

10,185

Contingent earn-out consideration liability, non-current

5,579

Other liabilities, non-current

19,093

9,383

Total liabilities

177,728

181,684

Stockholders' Equity

Preferred stock

Common stock

185

189

Additional paid-in capital

956,744

894,225

Accumulated other comprehensive income

1,396

1,323

Retained earnings

20,973

186,888

Total stockholders’ equity

979,298

1,082,625

Total liabilities and stockholders’ equity

$

1,157,026

$

1,264,309

DOXIMITY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended December 31,

Nine Months Ended December 31,

2025

2024

2025

2024

Revenue

$

185,053

$

168,603

$

499,491

$

432,111

Cost of revenue(1)

18,701

14,181

50,919

41,407

Gross profit

166,352

154,422

448,572

390,704

Operating expenses(1):

Research and development

34,595

22,421

91,596

68,235

Sales and marketing

42,205

38,491

117,738

108,102

General and administrative

17,656

13,585

49,144

32,943

Impairment charge

2,304

Total operating expenses

94,456

74,497

258,478

211,584

Income from operations

71,896

79,925

190,094

179,120

Other income, net

8,902

9,915

27,790

26,060

Income before income taxes

80,798

89,840

217,884

205,180

Provision for income taxes

19,240

14,644

40,947

44,453

Net income

$

61,558

$

75,196

$

176,937

$

160,727

Net income per share attributable to Class A and Class B common stockholders:

Basic

$

0.33

$

0.40

$

0.94

$

0.86

Diluted

$

0.31

$

0.37

$

0.88

$

0.80

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic

187,478

187,161

187,721

186,344

Diluted

199,224

202,233

200,375

200,625

(1)

Costs and expenses include stock-based compensation expense as follows (in thousands):

Three Months Ended December 31,

Nine Months Ended December 31,

2025

2024

2025

2024

Cost of revenue

$

2,899

$

2,818

$

8,723

$

8,373

Research and development

13,654

4,471

30,165

14,602

Sales and marketing

9,926

6,487

28,144

19,881

General and administrative

7,067

5,592

17,853

11,470

Total stock-based compensation expense

$

33,546

$

19,368

$

84,885

$

54,326

DOXIMITY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

Three Months Ended December 31,

Nine Months Ended December 31,

2025

2024

2025

2024

Cash flows from operating activities

Net income

$

61,558

$

75,196

$

176,937

$

160,727

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

3,989

2,655

10,252

7,830

Deferred income taxes

1,992

2,196

Stock-based compensation, net of amounts capitalized

33,546

19,368

84,885

54,326

Non-cash lease expense

459

441

1,363

1,392

Accretion of discount on marketable securities, net

(1,764

)

(3,368

)

(6,451

)

(8,736

)

Amortization of deferred contract costs

2,499

1,785

9,271

6,544

Impairment of long-lived assets

2,304

Other

295

411

181

289

Changes in operating assets and liabilities:

Accounts receivable

(27,614

)

(12,986

)

(28,599

)

(36,464

)

Prepaid expenses and other assets

(12,828

)

1,303

(9,377

)

21,251

Deferred contract costs

(6,710

)

(5,853

)

(11,259

)

(9,069

)

Accounts payable, accrued expenses and other liabilities

41,855

9,418

39,522

3,872

Deferred revenue

(33,816

)

(24,628

)

(48,084

)

(30,085

)

Operating lease liabilities

(578

)

(545

)

(1,705

)

(1,599

)

Net cash provided by operating activities

60,891

65,189

216,936

174,778

Cash flows from investing activities

Cash paid for acquisition, net of cash acquired

(26,528

)

Purchases of intangible assets

(62

)

(62

)

Internal-use software development costs

(2,313

)

(1,771

)

(6,648

)

(5,018

)

Purchases of marketable securities

(112,922

)

(164,025

)

(381,122

)

(531,833

)

Maturities of marketable securities

143,136

99,308

413,167

517,221

Sales of marketable securities

10,386

7,564

10,386

14,805

Net cash provided by (used in) investing activities

38,225

(58,924

)

9,193

(4,825

)

Cash flows from financing activities

Proceeds from issuance of common stock upon exercise of stock options and common stock warrants

2,221

3,662

7,017

13,905

Proceeds from issuance of common stock in connection with the employee stock purchase plan

1,816

1,422

Taxes paid related to net share settlement of equity awards

(8,869

)

(8,107

)

(33,362

)

(16,329

)

Repurchase of common stock

(196,879

)

(19,307

)

(341,127

)

(93,505

)

Payment of contingent consideration related to a business combination

(5,249

)

(5,470

)

Payment of excise taxes on share repurchases

(1,491

)

(1,491

)

Net cash used in financing activities

(203,527

)

(25,243

)

(370,905

)

(101,468

)

Net increase (decrease) in cash and cash equivalents

(104,411

)

(18,978

)

(144,776

)

68,485

Cash and cash equivalents, beginning of period

169,249

184,248

209,614

96,785

Cash and cash equivalents, end of period

$

64,838

$

165,270

$

64,838

$

165,270

Supplemental disclosures of cash flow information

Cash paid for taxes, net of refunds

$

1,675

$

13,829

$

21,022

$

35,814

Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:

  • Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of acquisition and other related expenses, stock-based compensation expense, amortization of acquired intangible assets, impairment charge, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, and change in fair value of contingent earn-out consideration liability from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
  • Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, impairment charge, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
  • Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment, purchases of intangible assets, and internal-use software development costs.

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Business Metrics

  • Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
  • Customers with trailing 12-month subscription revenue greater than $500,000: The number of customers with TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Three Months Ended December 31,

Nine Months Ended December 31,

2025

2024

2025

2024

(unaudited)

(in thousands, except percentages)

Net income

$

61,558

$

75,196

$

176,937

$

160,727

Adjusted to exclude the following:

Acquisition and other related expenses

1,616

Stock-based compensation

33,546

19,368

84,885

54,326

Depreciation and amortization

3,989

2,655

10,252

7,830

Provision for income taxes

19,240

14,644

40,947

44,453

Impairment charge

2,304

Change in fair value of contingent earn-out consideration liability

79

90

338

513

Legal expenses

1,886

4,813

Other income, net

(8,902

)

(9,915

)

(27,790

)

(26,060

)

Adjusted EBITDA

$

111,396

$

102,038

$

291,998

$

244,093

Revenue

$

185,053

$

168,603

$

499,491

$

432,111

Net income margin

33.3

%

44.6

%

35.4

%

37.2

%

Adjusted EBITDA margin

60.2

%

60.5

%

58.5

%

56.5

%

Three Months Ended December 31,

Nine Months Ended December 31,

2025

2024

2025

2024

(unaudited)

(in thousands)

Net cash provided by operating activities

$

60,891

$

65,189

$

216,936

$

174,778

Purchases of intangible assets

(62

)

(62

)

Internal-use software development costs

(2,313

)

(1,771

)

(6,648

)

(5,018

)

Free cash flow

$

58,516

$

63,418

$

210,226

$

169,760

Other cash flow components:

Net cash provided by (used in) investing activities

$

38,225

$

(58,924

)

$

9,193

$

(4,825

)

Net cash used in financing activities

$

(203,527

)

$

(25,243

)

$

(370,905

)

$

(101,468

)

Three Months Ended December 31,

Nine Months Ended December 31,

2025

2024

2025

2024

(unaudited)

(in thousands, except per share data and percentages)

GAAP cost of revenue

$

18,701

$

14,181

$

50,919

$

41,407

Adjusted to exclude the following:

Stock-based compensation

(2,899

)

(2,818

)

(8,723

)

(8,373

)

Non-GAAP cost of revenue

$

15,802

$

11,363

$

42,196

$

33,034

GAAP gross profit

$

166,352

$

154,422

$

448,572

$

390,704

Adjusted to exclude the following:

Stock-based compensation

2,899

2,818

8,723

8,373

Non-GAAP gross profit

$

169,251

$

157,240

$

457,295

$

399,077

GAAP gross margin

89.9

%

91.6

%

89.8

%

90.4

%

Non-GAAP gross margin

91.5

%

93.3

%

91.6

%

92.4

%

GAAP research and development expense

$

34,595

$

22,421

$

91,596

$

68,235

Adjusted to exclude the following:

Stock-based compensation

(13,654

)

(4,471

)

(30,165

)

(14,602

)

Amortization of acquired intangibles

(935

)

(1,558

)

Non-GAAP research and development expense

$

20,006

$

17,950

$

59,873

$

53,633

GAAP sales and marketing expense

$

42,205

$

38,491

$

117,738

$

108,102

Adjusted to exclude the following:

Stock-based compensation

(9,926

)

(6,487

)

(28,144

)

(19,881

)

Amortization of acquired intangibles

(1,003

)

(1,061

)

(3,007

)

(3,183

)

Change in fair value of contingent earn-out consideration liability

(79

)

(90

)

(338

)

(513

)

Non-GAAP sales and marketing expense

$

31,197

$

30,853

$

86,249

$

84,525

GAAP general and administrative expense

$

17,656

$

13,585

$

49,144

$

32,943

Adjusted to exclude the following:

Acquisition and other related expenses

(1,616

)

Stock-based compensation

(7,067

)

(5,592

)

(17,853

)

(11,470

)

Legal expenses

(1,886

)

(4,813

)

Non-GAAP general and administrative expense

$

8,703

$

7,993

$

24,862

$

21,473

GAAP operating expense

$

94,456

$

74,497

$

258,478

$

211,584

Adjusted to exclude the following:

Acquisition and other related expenses

(1,616

)

Stock-based compensation

(30,647

)

(16,550

)

(76,162

)

(45,953

)

Amortization of acquired intangibles

(1,938

)

(1,061

)

(4,565

)

(3,183

)

Change in fair value of contingent earn-out consideration liability

(79

)

(90

)

(338

)

(513

)

Legal expenses

(1,886

)

(4,813

)

Impairment charge

(2,304

)

Non-GAAP operating expense

$

59,906

$

56,796

$

170,984

$

159,631

GAAP operating income

$

71,896

$

79,925

$

190,094

$

179,120

Adjusted to exclude the following:

Acquisition and other related expenses

1,616

Stock-based compensation

33,546

19,368

84,885

54,326

Amortization of acquired intangibles

1,938

1,061

4,565

3,183

Change in fair value of contingent earn-out consideration liability

79

90

338

513

Legal expenses

1,886

4,813

Impairment charge

2,304

Non-GAAP operating income

$

109,345

$

100,444

$

286,311

$

239,446

GAAP net income

$

61,558

$

75,196

$

176,937

$

160,727

Adjusted to exclude the following:

Acquisition and other related expenses

1,616

Stock-based compensation

33,546

19,368

84,885

54,326

Amortization of acquired intangibles

1,938

1,061

4,565

3,183

Change in fair value of contingent earn-out consideration liability

79

90

338

513

Legal expenses

1,886

4,813

Impairment charge

2,304

Income tax effect of non-GAAP adjustments (1)

(7,864

)

(4,309

)

(20,206

)

(12,668

)

Non-GAAP net income

$

91,143

$

91,406

$

252,948

$

208,385

Non-GAAP net income margin

49.3

%

54.2

%

50.6

%

48.2

%

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic

187,478

187,161

187,721

186,344

Diluted

199,224

202,233

200,375

200,625

Non-GAAP net income per share attributable to Class A and Class B stockholders:

Basic

$

0.49

$

0.49

$

1.35

$

1.12

Diluted

$

0.46

$

0.45

$

1.26

$

1.04

(1)

For the three and nine months ended December 31, 2025 and 2024, management used an estimated annual effective non-GAAP tax rate of 21.0%.

Investor Relations Contact:
Perry Gold
ir@doximity.com

Media Contact:
Amanda Cox
pr@doximity.com

Source: Doximity